|
Report Date : |
01.03.2013 |
IDENTIFICATION DETAILS
|
Name : |
SANOFI WINTHROP INDUSTRIE SA |
|
|
|
|
Registered Office : |
20 avenue Raymond
Aron Antony, 92160 |
|
|
|
|
Country : |
France |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
15.01.1973 |
|
|
|
|
Com. Reg. No.: |
775662257 |
|
|
|
|
Legal Form : |
Public Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
5,442 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES
:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2011) |
Current Rating (30.06.2012) |
|
France |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
FRANCE - ECONOMIC OVERVIEW
France was transitioning from an economy that has featured extensive government ownership and intervention to one that relies more on market mechanisms but is in the midst of a euro-zone crisis. The government has partially or fully privatized many large companies, banks, and insurers, and has ceded stakes in such leading firms as Air France, France Telecom, Renault, and Thales. It maintains a strong presence in some sectors, particularly power, public transport, and defense industries. With at least 75 million foreign tourists per year, France is the most visited country in the world and maintains the third largest income in the world from tourism. France's leaders remain committed to a capitalism in which they maintain social equity by means of laws, tax policies, and social spending that reduce income disparity and the impact of free markets on public health and welfare. France's real GDP contracted 2.6% in 2009, but recovered somewhat in 2010 and 2011. The unemployment rate increased from 7.4% in 2008 to 9.3% in 2010 and 9.1% in 2011. Lower-than-expected growth and increased unemployment have cut government revenues and increased borrowing costs, contributing to a deterioration of France's public finances. The government budget deficit rose sharply from 3.4% of GDP in 2008 to 7.5% of GDP in 2009 before improving to 5.8% of GDP in 2011, while France's public debt rose from 68% of GDP to 86% over the same period. Under President SARKOZY, Paris implemented austerity measures that eliminated tax credits and froze most government spending in an effort to bring the budget deficit under the 3% euro-zone ceiling by 2013 and to highlight France's commitment to fiscal discipline at a time of intense financial market scrutiny of euro-zone debt levels. Socialist Francois HOLLANDE won the May 2012 presidential election, after advocating pro-growth economic policies, as well as measures such as forcing banks to separate their traditional deposit taking and lending activities from more speculative businesses, increasing taxes on bank profits, introducing a new top bracket on income taxes for people earning over €1 million ($1.3 million) a year, and hiring an additional 60,000 civil servants during his five-year term of office.
Source : CIA
Sanofi Winthrop Industrie SA
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||
Business Description
|
Sanofi Winthrop Industrie is primarily
engaged in production of medicinally active substances to be used for their pharmacological
properties in the manufacture of medicaments; and processing of blood. This
class also includes: manufacture of chemically pure sugars; and processing of
glands and manufacture of extracts of glands, etc. |
Industry
|
Industry |
|
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal Product
Manufacturing |
|
NACE 2002: |
|
|
NAICS 2002: |
|
|
UK SIC 2003: |
|
|
UK SIC 2007: |
|
|
US SIC 1987: |
Key Executives
|
1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7191895
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.770327
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sanofi Winthrop Industrie SA |
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
Paris |
France |
Biotechnology and Drugs |
46,203.2 |
113,719 |
|
|
Subsidiary |
Bridgewater, NJ |
United States |
Miscellaneous Financial Services |
2,700.0 |
11,400 |
|
|
Subsidiary |
Bridgewater, NJ |
United States |
Biotechnology and Drugs |
|
10,000 |
|
|
Subsidiary |
Kansas City, MO |
United States |
Biotechnology and Drugs |
|
|
|
|
Unit |
Malvern, PA |
United States |
Business Services |
|
|
|
|
Branch |
Bridgewater, NJ |
United States |
Retail (Drugs) |
155.5 |
500 |
|
|
Branch |
Malvern, PA |
United States |
Biotechnology and Drugs |
|
500 |
|
|
Division |
Kansas City, MO |
United States |
Biotechnology and Drugs |
299.0 |
300 |
|
|
Branch |
St Louis, MO |
United States |
Business Services |
0.6 |
90 |
|
|
Branch |
Oro Valley, AZ |
United States |
Biotechnology and Drugs |
|
40 |
|
|
Branch |
Scottsdale, AZ |
United States |
Personal and Household Products |
82.1 |
32 |
|
|
Branch |
Reston, VA |
United States |
Personal and Household Products |
19.6 |
8 |
|
|
Branch |
Cambridge, MA |
United States |
Retail (Drugs) |
2.0 |
7 |
|
|
Branch |
Wilmington, DE |
United States |
Business Services |
0.4 |
3 |
|
|
Subsidiary |
Cambridge, MA |
United States |
Biotechnology and Drugs |
4,048.7 |
10,100 |
|
|
Division |
Framingham, MA |
United States |
Biotechnology and Drugs |
|
8,000 |
|
|
Division |
Cambridge, MA |
United States |
Biotechnology and Drugs |
|
7,000 |
|
|
Subsidiary |
New York, NY |
United States |
Healthcare Facilities |
188.1 |
1,136 |
|
|
Division |
Cambridge, MA |
United States |
Biotechnology and Drugs |
237.9 |
800 |
|
|
Subsidiary |
New York, NY |
United States |
Healthcare Facilities |
114.2 |
600 |
|
|
Subsidiary |
Geel |
Belgium |
Biotechnology and Drugs |
228.8 |
522 |
|
|
Subsidiary |
Waterford |
Ireland |
Biotechnology and Drugs |
1,298.4 |
472 |
|
|
Subsidiary |
Naarden |
Netherlands |
Biotechnology and Drugs |
1,089.2 |
450 |
|
|
Subsidiary |
Neu-Isenburg, Hessen |
Germany |
Personal and Household Products |
190.4 |
185 |
|
|
Subsidiary |
Neu-Isenburg, Hessen |
Germany |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Oxford |
United Kingdom |
Personal and Household Products |
152.8 |
181 |
|
|
Subsidiary |
Modena |
Italy |
Biotechnology and Drugs |
151.7 |
109 |
|
|
Subsidiary |
Warszawa |
Poland |
Personal and Household Products |
7.9 |
10 |
|
|
Subsidiary |
Neu-Isenburg, Hessen |
Germany |
Commercial Banks |
|
1 |
|
|
Branch |
Los Angeles, CA |
United States |
Biotechnology and Drugs |
|
400 |
|
|
Subsidiary |
Ridgefield, NJ |
United States |
Biotechnology and Drugs |
200.0 |
300 |
|
|
Subsidiary |
Santa Fe, NM |
United States |
Business Services |
|
250 |
|
|
Subsidiary |
San Antonio, TX |
United States |
Biotechnology and Drugs |
|
225 |
|
|
Subsidiary |
Moscow |
Russian Federation |
Personal and Household Products |
7.5 |
164 |
|
|
Subsidiary |
Mississauga, ON |
Canada |
Biotechnology and Drugs |
109.0 |
150 |
|
|
Subsidiary |
San Antonio, TX |
United States |
Biotechnology and Drugs |
|
110 |
|
|
Subsidiary |
Phoenix, AZ |
United States |
Biotechnology and Drugs |
|
110 |
|
|
Branch |
Monrovia, CA |
United States |
Biotechnology and Drugs |
|
100 |
|
|
Division |
Framingham, MA |
United States |
Business Services |
|
100 |
|
|
Branch |
Waltham, MA |
United States |
Biotechnology and Drugs |
9.5 |
95 |
|
|
Branch |
San Diego, CA |
United States |
Biotechnology and Drugs |
50.6 |
84 |
|
|
Branch |
Allston, MA |
United States |
Biotechnology and Drugs |
44.6 |
84 |
|
|
Branch |
Cambridge, MA |
United States |
Biotechnology and Drugs |
44.6 |
84 |
|
|
Branch |
Framingham, MA |
United States |
Biotechnology and Drugs |
44.6 |
84 |
|
|
Branch |
Framingham, MA |
United States |
Biotechnology and Drugs |
44.6 |
84 |
|
|
Branch |
Middleton, WI |
United States |
Biotechnology and Drugs |
10.7 |
70 |
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
|
70 |
|
|
Branch |
Tampa, FL |
United States |
Business Services |
|
60 |
|
|
Subsidiary |
Copenhagen |
Denmark |
Biotechnology and Drugs |
0.0 |
35 |
|
|
Subsidiary |
Zaventem |
Belgium |
Biotechnology and Drugs |
41.2 |
34 |
|
|
Subsidiary |
Boulogne |
Argentina |
Biotechnology and Drugs |
|
27 |
|
|
Branch |
Exton, PA |
United States |
Biotechnology and Drugs |
11.5 |
18 |
|
|
Subsidiary |
St Germain En Laye |
France |
Personal and Household Products |
290.2 |
14 |
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
207.2 |
224 |
|
|
Branch |
Philadelphia, PA |
United States |
Biotechnology and Drugs |
53.8 |
12 |
|
|
Subsidiary |
Long Beach, CA |
United States |
Healthcare Facilities |
1.4 |
6 |
|
|
Branch |
Washington, DC |
United States |
Biotechnology and Drugs |
0.9 |
3 |
|
|
Subsidiary |
Sao Paulo |
Brazil |
Biotechnology and Drugs |
|
|
|
|
Branch |
Rio De Janeiro, Rio De Janeiro |
Brazil |
Medical Equipment and Supplies |
|
|
|
|
Subsidiary |
Porto Salvo |
Portugal |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Johannesburg, Bryanston |
South Africa |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Mexico |
Mexico |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Santiago |
Chile |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Bogota |
Colombia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Lima |
Peru |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Vienna |
Austria |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Paris, Saint Germain |
France |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Athens |
Greece |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Kefar Sava |
Israel |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Gurgaon, Haryana |
India |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Seoul, KangNam-Ku |
Korea, Republic of |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Petaling Jaya, Selangor Darul Ehsan |
Malaysia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
North Ryde |
Australia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Geel |
Belgium |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Madrid |
Spain |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
|
|
|
|
Genzyme Australasia Pty Ltd |
Subsidiary |
|
|
|
|
|
|
Subsidiary |
Amsterdam |
Netherlands |
Biotechnology and Drugs |
|
6,000 |
|
|
Subsidiary |
Praha 10, Dolni Mecholupy |
Czech Republic |
Miscellaneous Financial Services |
89.4 |
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Miscellaneous Capital Goods |
195.8 |
716 |
|
|
Subsidiary |
Duluth, GA |
United States |
Biotechnology and Drugs |
2,700.0 |
5,600 |
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
1,056.2 |
1,792 |
|
|
Subsidiary |
Paulinia, Sao Paulo |
Brazil |
Biotechnology and Drugs |
239.2 |
526 |
|
|
Subsidiary |
Assago, Milano |
Italy |
Personal and Household Products |
191.3 |
169 |
|
|
Subsidiary |
Ancenis |
France |
Biotechnology and Drugs |
36.7 |
149 |
|
|
Subsidiary |
Hallbergmoos, Bayern |
Germany |
Biotechnology and Drugs |
75.9 |
90 |
|
|
Subsidiary |
Manukau |
New Zealand |
Medical Equipment and Supplies |
61.0 |
70 |
|
|
Subsidiary |
Singapore |
Singapore |
Personal and Household Products |
1,194.7 |
35 |
|
|
Subsidiary |
Porto Salvo, Oeiras |
Portugal |
Personal and Household Products |
16.5 |
27 |
|
|
Subsidiary |
Velserbroek, North Holland |
Netherlands |
Biotechnology and Drugs |
|
23 |
|
|
Subsidiary |
Shinjuku-Ku, Tokyo |
Japan |
Personal and Household Products |
74.1 |
|
|
|
Subsidiary |
Harlow |
United Kingdom |
Biotechnology and Drugs |
1,312.6 |
1,246 |
|
|
Subsidiary |
Parramatta, NSW |
Australia |
Medical Equipment and Supplies |
6.7 |
100 |
|
|
Subsidiary |
Tokyo |
Japan |
Medical Equipment and Supplies |
|
|
|
|
Subsidiary |
Walpole, NH |
United States |
Fish and Livestock |
|
810 |
|
|
Subsidiary |
Sinks Grove, WV |
United States |
Fish and Livestock |
7.8 |
15 |
|
|
Subsidiary |
Monroe, OR |
United States |
Crops |
1.9 |
9 |
|
|
Subsidiary |
Duluth, GA |
United States |
Biotechnology and Drugs |
19.7 |
300 |
|
|
Branch |
Athens, GA |
United States |
Biotechnology and Drugs |
9.3 |
260 |
|
|
Subsidiary |
Gainesville, GA |
United States |
Biotechnology and Drugs |
|
250 |
|
|
Subsidiary |
Skovlunde |
Denmark |
Food Processing |
0.0 |
100 |
|
|
Subsidiary |
Barcelona |
Spain |
Biotechnology and Drugs |
50.9 |
58 |
|
|
Subsidiary |
Martinez, Buenos Aires |
Argentina |
Personal and Household Products |
33.1 |
47 |
|
|
Subsidiary |
Diegem |
Belgium |
Food Processing |
24.4 |
25 |
|
|
Branch |
Fulton, MO |
United States |
Biotechnology and Drugs |
10.0 |
10 |
|
|
Branch |
Roseville, CA |
United States |
Biotechnology and Drugs |
9.0 |
10 |
|
|
Subsidiary |
Montreal, QC |
Canada |
Biotechnology and Drugs |
11.1 |
6 |
|
|
Subsidiary |
Bogota, Cundinamarca |
Colombia |
Forestry and Wood Products |
|
4 |
|
|
Subsidiary |
El Marques, Queretaro |
Mexico |
Food Processing |
7.5 |
|
|
|
Subsidiary |
Sao Paulo |
Brazil |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Duluth, GA |
United States |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Antony |
France |
Biotechnology and Drugs |
31.8 |
4,593 |
|
|
Subsidiary |
Moscow |
Russian Federation |
Personal and Household Products |
682.2 |
|
|
|
Subsidiary |
Paris |
France |
Chemical Manufacturing |
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
100.3 |
25 |
|
|
Subsidiary |
Campinas, SP |
Brazil |
Biotechnology and Drugs |
1,607.7 |
3,800 |
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
1,405.2 |
3,499 |
|
|
Subsidiary |
Amman |
Jordan |
Personal and Household Products |
|
|
|
|
Subsidiary |
Ciudad De Mexico, Distrito Federal |
Mexico |
Personal and Household Products |
26.4 |
3,200 |
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
3,629.1 |
3,053 |
|
|
Subsidiary |
Chilly Mazarin |
France |
Biotechnology and Drugs |
1,746.5 |
6,777 |
|
|
Branch |
Strasbourg, Bas Rhin |
France |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
Quito, Pichincha |
Ecuador |
Personal and Household Products |
3.4 |
50 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
293.5 |
2,943 |
|
|
Subsidiary |
México, D.F. |
Mexico |
Biotechnology and Drugs |
724.1 |
2,450 |
|
|
Subsidiary |
Dhaka |
Bangladesh |
Biotechnology and Drugs |
|
1,200 |
|
|
Subsidiary |
Praha |
Czech Republic |
Biotechnology and Drugs |
407.0 |
1,130 |
|
|
Subsidiary |
Hlohovec |
Slovakia |
Biotechnology and Drugs |
284.4 |
923 |
|
|
Subsidiary |
Bucuresti |
|
Biotechnology and Drugs |
82.1 |
532 |
|
|
Subsidiary |
München, Bayern |
Germany |
Biotechnology and Drugs |
|
67 |
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
497.6 |
1,120 |
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
1,000 |
|
|
Affiliates |
Frankfurt Am Main, Hessen |
Germany |
Biotechnology and Drugs |
6,268.7 |
9,400 |
|
|
Subsidiary |
Köln, Nordrhein-Westfalen |
Germany |
Biotechnology and Drugs |
178.6 |
400 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Biotechnology and Drugs |
158.2 |
1 |
|
|
Subsidiary |
Mexico |
Mexico |
Biotechnology and Drugs |
|
7,000 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
290.0 |
2,943 |
|
|
Branch |
Mumbai, Maharashtra |
India |
Chemical Manufacturing |
|
75 |
|
|
Branch |
Mumbai, Maharashtra |
India |
Biotechnology and Drugs |
|
70 |
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
1,900.0 |
2,250 |
|
|
Subsidiary |
Laval, QC |
Canada |
Biotechnology and Drugs |
540.1 |
1,700 |
|
|
Subsidiary |
Saint-Laurent, QC |
Canada |
Personal and Household Products |
120.0 |
51 |
|
|
Subsidiary |
Barcelona |
Spain |
Biotechnology and Drugs |
999.6 |
1,600 |
|
|
Subsidiary |
Macquarie Park, NSW |
Australia |
Biotechnology and Drugs |
597.8 |
1,000 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
|
500 |
|
|
Subsidiary |
Frankfurt |
Germany |
Biotechnology and Drugs |
|
500 |
|
|
Subsidiary |
Bangkok |
Thailand |
Biotechnology and Drugs |
|
350 |
|
|
Subsidiary |
Vienna |
Austria |
Biotechnology and Drugs |
|
220 |
|
|
Subsidiary |
Gouda |
Netherlands |
Biotechnology and Drugs |
|
160 |
|
|
Subsidiary |
Bromma |
Sweden |
Personal and Household Products |
112.7 |
144 |
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
140 |
|
|
Subsidiary |
Lima |
Peru |
Biotechnology and Drugs |
|
120 |
|
|
Subsidiary |
Causeway Bay |
Hong Kong |
Personal and Household Products |
|
100 |
|
|
Subsidiary |
Lysaker |
Norway |
Biotechnology and Drugs |
|
90 |
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
54.9 |
83 |
|
|
Subsidiary |
Quito |
Ecuador |
Biotechnology and Drugs |
|
70 |
|
|
Subsidiary |
Geneva |
Switzerland |
Biotechnology and Drugs |
|
11 |
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Lainate, MI |
Italy |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Midrand |
South Africa |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Warszawa |
Poland |
Biotechnology and Drugs |
595.7 |
732 |
|
|
Subsidiary |
Cairo |
Egypt |
Biotechnology and Drugs |
|
716 |
|
|
Subsidiary |
Cuautitlan Izcalli, Estado De Mexico |
Mexico |
Biotechnology and Drugs |
94.6 |
600 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Personal and Household Products |
602.3 |
581 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
98.4 |
23 |
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
575 |
|
|
Subsidiary |
Makati |
Philippines |
Biotechnology and Drugs |
|
570 |
|
|
Subsidiary |
Chattanooga, TN |
United States |
Biotechnology and Drugs |
463.3 |
547 |
|
|
Branch |
Coral Gables, FL |
United States |
Business Services |
1.0 |
5 |
|
|
Subsidiary |
Basingstoke |
United Kingdom |
Personal and Household Products |
2.4 |
4 |
|
|
Branch |
Redondo Beach, CA |
United States |
Business Services |
8.1 |
3 |
|
|
Branch |
Chattanooga, TN |
United States |
Retail (Drugs) |
0.6 |
2 |
|
|
Branch |
Roseville, CA |
United States |
Retail (Specialty) |
0.5 |
2 |
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
500 |
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
450 |
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
450 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
310.5 |
410 |
|
|
Subsidiary |
Virginia, QLD |
Australia |
Biotechnology and Drugs |
29.3 |
400 |
|
|
Subsidiary |
San Isidro, Buenos Aires |
Argentina |
Biotechnology and Drugs |
99.8 |
300 |
|
|
Subsidiary |
Vernier |
Switzerland |
Personal and Household Products |
20,760.0 |
270 |
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Biotechnology and Drugs |
63.7 |
250 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
74.4 |
248 |
|
|
Subsidiary |
Kallithea, Athens |
Greece |
Biotechnology and Drugs |
382.2 |
240 |
|
|
Subsidiary |
Diegem |
Belgium |
Biotechnology and Drugs |
308.3 |
214 |
|
|
Subsidiary |
Vilnius |
Lithuania |
Biotechnology and Drugs |
58.0 |
200 |
|
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
200 |
|
|
Subsidiary |
Harlow |
United Kingdom |
Biotechnology and Drugs |
124.7 |
187 |
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
185 |
|
|
Subsidiary |
Kiev |
Ukraine |
Biotechnology and Drugs |
173.4 |
150 |
|
|
Subsidiary |
Wien |
Austria |
Biotechnology and Drugs |
161.0 |
148 |
|
|
Subsidiary |
Beirut |
Lebanon |
Personal and Household Products |
|
147 |
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
1,281.8 |
131 |
|
|
Subsidiary |
Netanya |
Israel |
Personal and Household Products |
24.8 |
100 |
|
|
Subsidiary |
Las Condes, Santiago |
Chile |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Geneva |
Switzerland |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Kuala Lumpur, Kuala Lumpur |
Malaysia |
Retail (Grocery) |
|
60 |
|
|
Subsidiary |
Bratislava |
Slovakia |
Biotechnology and Drugs |
|
98 |
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
83.4 |
88 |
|
|
Subsidiary |
Horsholm |
Denmark |
Biotechnology and Drugs |
71.0 |
85 |
|
|
Subsidiary |
Dakar |
Senegal |
Personal and Household Products |
|
80 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
|
70 |
|
|
Subsidiary |
Lysaker |
Norway |
Biotechnology and Drugs |
69.4 |
54 |
|
|
Subsidiary |
Paris |
France |
Personal and Household Products |
70.4 |
50 |
|
|
Subsidiary |
Saint Laurent, QC |
Canada |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
Saint Laurent, QC |
Canada |
Personal and Household Products |
|
50 |
|
|
Subsidiary |
Amman |
Jordan |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
San Diego, CA |
United States |
Biotechnology and Drugs |
|
46 |
|
|
Subsidiary |
Lagos |
Nigeria |
Personal and Household Products |
|
40 |
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
166.3 |
39 |
|
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
8.1 |
35 |
|
|
Subsidiary |
Tallinn |
Estonia |
Biotechnology and Drugs |
4.6 |
35 |
|
|
Subsidiary |
Woburn, MA |
United States |
Medical Equipment and Supplies |
14.9 |
30 |
|
|
Subsidiary |
Montevideo |
Uruguay |
Retail (Drugs) |
|
30 |
|
|
Subsidiary |
Paris |
France |
Business Services |
0.0 |
28 |
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
6.3 |
25 |
|
|
Subsidiary |
Damascus |
Syria |
Biotechnology and Drugs |
|
25 |
|
|
Subsidiary |
South San Francisco, CA |
United States |
Business Services |
|
20 |
|
|
Subsidiary |
Kuwait |
Kuwait |
Biotechnology and Drugs |
|
15 |
|
|
Subsidiary |
Strovolos, Nicosia |
Cyprus |
Biotechnology and Drugs |
|
12 |
|
|
Subsidiary |
Horsham, PA |
United States |
Biotechnology and Drugs |
|
4 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Commercial Banks |
|
2 |
|
|
Subsidiary |
Paris |
France |
Personal and Household Products |
950.7 |
|
|
|
Subsidiary |
Ciudad De Mexico, Distrito Federal |
Mexico |
Biotechnology and Drugs |
862.8 |
|
|
|
Subsidiary |
Mexico City, Distrito Federal |
Mexico |
Biotechnology and Drugs |
35.0 |
392 |
|
|
Subsidiary |
Bogotá DC |
Colombia |
Personal and Household Products |
211.3 |
|
|
|
Subsidiary |
Antony |
France |
Personal and Household Products |
0.2 |
|
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
2,045.6 |
4,500 |
|
|
Subsidiary |
Marcy-l'Etoile, Lyon |
France |
Business Services |
|
8,000 |
|
|
Subsidiary |
Swiftwater, PA |
United States |
Biotechnology and Drugs |
554.0 |
4,000 |
|
|
Branch |
Taylor, PA |
United States |
Personal and Household Products |
12.4 |
5 |
|
|
Branch |
Duluth, GA |
United States |
Personal and Household Products |
4.9 |
2 |
|
|
Subsidiary |
Lyon, Rouen |
France |
Business Services |
|
1,500 |
|
|
Subsidiary |
Toronto, ON |
Canada |
Biotechnology and Drugs |
12.7 |
1,100 |
|
|
Subsidiary |
North Ryde, NSW |
Australia |
Biotechnology and Drugs |
|
400 |
|
|
Subsidiary |
Cambridge |
United Kingdom |
Biotechnology and Drugs |
18.8 |
206 |
|
|
Subsidiary |
Cambridge, MA |
United States |
Biotechnology and Drugs |
|
160 |
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
|
200 |
|
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
|
200 |
|
|
Subsidiary |
San Isidro, Buenos Aires |
Argentina |
Biotechnology and Drugs |
|
130 |
|
|
Subsidiary |
Manila, Makati |
Philippines |
Biotechnology and Drugs |
|
70 |
|
|
Subsidiary |
Orlando, FL |
United States |
Biotechnology and Drugs |
|
70 |
|
|
Subsidiary |
Mexico |
Mexico |
Biotechnology and Drugs |
|
65 |
|
|
Subsidiary |
Bangkok |
Thailand |
Biotechnology and Drugs |
|
55 |
|
|
Subsidiary |
Santiago |
Chile |
Biotechnology and Drugs |
|
45 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
33.3 |
35 |
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
35 |
|
|
Subsidiary |
Bogota, DC |
Colombia |
Biotechnology and Drugs |
|
35 |
|
|
Subsidiary |
Bogota, Cundinamarca |
Colombia |
Medical Equipment and Supplies |
14.8 |
32 |
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
|
30 |
|
|
Subsidiary |
Abidjan |
Cote d'Ivoire |
Personal and Household Products |
|
26 |
|
|
Subsidiary |
San Isidro, Lima |
Peru |
Biotechnology and Drugs |
|
20 |
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
|
12 |
|
|
Subsidiary |
Budapest |
Hungary |
Personal and Household Products |
|
6 |
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Biotechnology and Drugs |
|
4 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
2 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
14.4 |
|
|
|
Subsidiary |
New Delhi |
India |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Hyderabad, |
India |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Beijing |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Shenzhen |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Beijing |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Johannesburg |
South Africa |
Personal and Household Products |
|
|
|
|
Subsidiary |
Scranton, PA |
United States |
Medical Equipment and Supplies |
|
|
|
|
Subsidiary |
Santo Domingo |
Dominican Republic |
Chemical Manufacturing |
|
|
|
|
Subsidiary |
Mixco |
Guatemala |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Lima |
Peru |
Personal and Household Products |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
922.2 |
458 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
122.6 |
383 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Personal and Household Products |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Megrine |
Tunisia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Taipei |
Taiwan |
Personal and Household Products |
|
|
|
|
Subsidiary |
Beijing, Beijing |
China |
Business Services |
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Business Services |
|
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Jeddah |
Saudi Arabia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Caracas, Distrito Federal |
Venezuela |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Midrand |
South Africa |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Nairobi |
Kenya |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Algiers |
Algeria |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Antony |
France |
Biotechnology and Drugs |
14,409.5 |
5,442 |
|
|
Subsidiary |
Gentilly |
France |
Chemical Manufacturing |
2,019.5 |
4,202 |
|
|
Subsidiary |
Paris |
France |
Chemical Manufacturing |
169.7 |
40 |
|
|
Subsidiary |
Milano |
Italy |
Biotechnology and Drugs |
1,971.3 |
2,703 |
|
|
Subsidiary |
Milano, Milano |
Italy |
Construction and Agriculture Machinery |
0.0 |
1 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Miscellaneous Financial Services |
|
500 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Gouda, Zuid-Holland |
Netherlands |
Miscellaneous Capital Goods |
181.4 |
207 |
|
|
Subsidiary |
Veghel, Noord-Brabant |
Netherlands |
Biotechnology and Drugs |
|
27 |
|
|
Subsidiary |
Helsinki |
Finland |
Personal and Household Products |
110.4 |
113 |
|
|
Subsidiary |
Guildford |
United Kingdom |
Personal and Household Products |
|
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Panama |
Panama |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Oeiras, Porto Salvo |
Portugal |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Asuncion |
Paraguay |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Ljubljana |
Slovenia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Beijing |
China |
Personal and Household Products |
|
|
|
|
Subsidiary |
Oeiras |
Portugal |
Personal and Household Products |
|
|
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Personal and Household Products |
|
|
|
|
Subsidiary |
Almaty |
Kazakhstan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Tbilisi |
Georgia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Paris |
France |
Personal and Household Products |
|
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
1,759.2 |
2,500 |
|
|
Subsidiary |
Porto Salvo, Lisboa |
Portugal |
Biotechnology and Drugs |
131.4 |
297 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Commercial Banks |
|
4 |
|
|
Subsidiary |
Durban, Kwazulu-Natal |
South Africa |
Chemical Manufacturing |
|
1,450 |
|
|
Branch |
Mumbai, Maharashtra |
India |
Chemicals - Plastics and Rubber |
|
353 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Real Estate Operations |
|
14 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Commercial Banks |
|
3 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Chemicals - Plastics and Rubber |
|
3 |
|
|
Subsidiary |
Abidjan |
Cote d'Ivoire |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Dakar |
Senegal |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Beijing |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Wilmington, DE |
United States |
Investment Services |
|
|
|
|
Subsidiary |
Orel |
Russian Federation |
Biotechnology and Drugs |
|
|
Executives
Report
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate (Period Average) |
0.71919 |
0.755078 |
0.719047 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total income |
14,668.9 |
14,707.1 |
15,285.2 |
|
Net sales |
14,409.5 |
14,610.7 |
15,172.6 |
|
Change in stock |
28.3 |
-252.4 |
-95.5 |
|
Unfinished work in progress |
-29.8 |
-30.8 |
-190.4 |
|
Own work capitalised |
- |
- |
1.3 |
|
Subsidies for operating costs |
1.2 |
1.2 |
0.8 |
|
Supplementary operating income |
95.4 |
106.3 |
277.4 |
|
Other operating income |
192.6 |
19.7 |
23.6 |
|
Other external charges |
2,145.2 |
2,067.9 |
2,147.6 |
|
Cost of goods sold |
8,519.5 |
8,613.7 |
8,453.4 |
|
Taxes and social security costs |
85.8 |
83.8 |
78.2 |
|
Social charges |
208.5 |
195.9 |
202.8 |
|
Total payroll costs |
382.4 |
353.2 |
378.9 |
|
Cost of stock depreciation and amortisation |
152.7 |
123.6 |
111.7 |
|
Fixed asset depreciation and amortisation |
99.0 |
94.3 |
100.4 |
|
Other operating costs |
1,959.9 |
2,069.6 |
2,798.3 |
|
Total operating costs |
13,581.4 |
13,349.5 |
14,175.7 |
|
Net operating income |
1,087.5 |
1,357.6 |
1,109.5 |
|
Total financial income |
133.8 |
118.4 |
98.1 |
|
Interest payable on loans |
22.8 |
16.9 |
12.5 |
|
Other expenses |
129.3 |
113.0 |
89.9 |
|
Total expenses |
152.1 |
129.9 |
102.4 |
|
Profit before tax |
1,069.1 |
1,346.1 |
1,105.2 |
|
Extraordinary income |
19.1 |
27.4 |
83.2 |
|
Extraordinary expenses |
33.8 |
34.7 |
185.7 |
|
Extraordinary result |
-14.7 |
-7.3 |
-102.5 |
|
Total taxation |
368.3 |
552.1 |
467.2 |
|
Profit distributed to employees |
48.7 |
44.7 |
46.9 |
|
Net profit |
637.4 |
742.0 |
488.6 |
|
|
|
Annual Balance Sheet |
|
Financials in: USD (mil) |
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.770327 |
0.745406 |
0.696986 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Issued capital |
345.4 |
357.0 |
381.8 |
|
Share premium account |
204.0 |
210.6 |
225.2 |
|
Legal reserves |
120.6 |
114.3 |
106.5 |
|
Total reserves |
49.6 |
51.3 |
54.9 |
|
Profits for the year |
595.1 |
751.6 |
504.1 |
|
Profit brought forward from previous
year(s) |
0.8 |
1.1 |
3.0 |
|
Capital subsidies and grants |
0.2 |
0.1 |
0.2 |
|
Total stockholders equity |
1,315.7 |
1,485.9 |
1,275.5 |
|
Provisions and allowances |
350.7 |
317.1 |
338.5 |
|
Trade creditors |
2,777.7 |
2,578.4 |
3,007.3 |
|
Bank loans and overdrafts |
43.4 |
33.2 |
30.7 |
|
Current bank debts |
43.4 |
33.2 |
30.7 |
|
Other loans |
944.1 |
774.3 |
765.8 |
|
Other liabilities |
163.7 |
72.0 |
84.2 |
|
Debts on fixed assets |
6.1 |
13.8 |
15.6 |
|
Income stated in advance |
8.8 |
2.2 |
3.4 |
|
Taxation and social security |
558.7 |
783.0 |
690.1 |
|
Total current liabilities |
4,496.7 |
4,255.2 |
4,591.8 |
|
Total debts |
4,502.6 |
4,256.9 |
4,597.1 |
|
Regularisation account |
85.6 |
43.6 |
37.3 |
|
Total liabilities (including net worth) |
6,254.6 |
6,103.5 |
6,248.3 |
|
Patents |
7.0 |
6.4 |
10.1 |
|
Other intangibles |
1.1 |
3.7 |
0.6 |
|
Land |
21.1 |
22.0 |
21.7 |
|
Buildings |
242.7 |
255.4 |
267.7 |
|
Other fixed assets |
414.4 |
434.1 |
472.0 |
|
Long-term investments |
0.6 |
0.1 |
0.0 |
|
Other financial assets |
5.3 |
6.1 |
6.4 |
|
Total non-current assets |
692.2 |
727.8 |
778.6 |
|
Prepayments |
0.5 |
0.9 |
1.7 |
|
Net stocks and work in progress |
969.9 |
1,038.3 |
868.9 |
|
Trade debtors |
3,231.4 |
3,042.0 |
3,497.6 |
|
Other receivables |
1,207.3 |
1,184.3 |
990.0 |
|
Prepaid expenses |
12.0 |
43.8 |
42.4 |
|
Cash and liquid assets |
54.2 |
22.3 |
27.5 |
|
Total current assets |
5,475.3 |
5,331.5 |
5,428.1 |
|
Prepaid expenses and deferred costs |
87.2 |
44.3 |
41.6 |
|
Total assets |
6,254.6 |
6,103.5 |
6,248.3 |
|
|
|
Annual Ratios |
|
Financials in: USD (mil) |
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.770327 |
0.745406 |
0.696986 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Current ratio |
1.20 |
1.30 |
1.20 |
|
Quick ratio |
1.00 |
1.00 |
1.00 |
|
Total liabilities to net worth |
3.69% |
2.97% |
3.76% |
|
Net worth to total assets |
0.20% |
0.24% |
0.20% |
|
Collection period |
72.90 |
62.40 |
67.80 |
|
Stock turnover rate |
13.90 |
14.30 |
18.00 |
|
Asset turnover |
2.15% |
2.43% |
2.51% |
|
Profit margin |
0.07% |
0.09% |
0.07% |
|
Return on assets |
0.16% |
0.22% |
0.18% |
|
Shareholders' return |
0.82% |
0.95% |
0.93% |
|
Sales per employee |
12,491.33 |
13,224.93 |
12,763.30 |
|
Profit per employee |
926.81 |
1,218.41 |
929.70 |
|
Average wage per employee |
331.50 |
319.67 |
318.71 |
|
Net worth |
1,315.7 |
1,485.9 |
1,275.5 |
|
Number of employees |
5,442 |
5,472 |
5,607 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.77 |
|
|
1 |
Rs.81.57 |
|
Euro |
1 |
Rs.70.68 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.